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PCASE4
DIVERSITY OF ANTIBIOTIC USE AND BACTERIAL
RESISTANCE
Polk R1, Pakyz A2, Oinonen M3
1Virginia Commonwealth University School of Pharmacy, School of
Pharmacy,VA, USA, 2Virginia Commonwealth University, Richmond,
VA, USA, 3University HealthSystem Consortium, Oak Brook, IL, USA
Organization: The University HealthSystem Consortium (UHC;
http://www.uhc.edu) hospitals and Virginia Commonwealth 
University.
Problem or Issue Addressed: Nationwide rates of bacterial resis-
tance among nosocomial pathogens are increasing. Mathemati-
cal models and limited clinical data suggest that greater diversity
(or heterogeneity) of antibiotic use may decrease rates of 
resistance.
Goals: The goal of this investigation is to determine if an increase
in diversity of antibiotic use at UHC hospitals will be associated
with an improvement in rates of resistance. The UHC is an
alliance of 97 academic medical centers and afﬁliated hospitals.
UHC hospitals that also subscribe to the Clinical Resource
Manager program were asked to participate in a long-term, mul-
tihospital antimicrobial use and surveillance program in 2003.
We retrieved claims data for systemic antibiotic use administered
to adult inpatients beginning in year 2002 (N = 31 hospitals) and
through 2005 (N = 35 hospitals). Using 5 classes of antibiotics
that are commonly administered for treatment of nosocomial
infections (aminoglycosides, 3/4th generation cephalosporins,
ﬂuoroquinolones, carbapenems, and b-lactamase inhibitor com-
binations) we applied Simpson’s Index of Diversity (D) to arrive
at a diversity measure for each hospital. We also collected annual
antibiograms from most hospitals for 2002 through 2004, and
we focused on methicillin-resistant Staphylococcus aureus
(MRSA) and ﬂuoroquinolone-resistant Pseudomonas aeruginosa
(FQRPa). We determined both the proportion of resistant iso-
lates (% resistant) and the rate of resistance isolates (no. organ-
isms/1000 admissions) for MRSA and FQRPa. Hospitals with a
Diversity Index less than the median diversity value for year
2004 (i.e., D < 0.722) were offered an educational intervention.
The intervention consisted of a visit to each hospital by the prin-
cipal investigator (PI, REP) at the investigator’s expense. During
the visit, a 45 minute educational presentation was given to the
hospital antibiotic committee regarding the potential merits of
diversity of antibiotic use, and to provide benchmarking infor-
mation regarding diversity and resistance in MRSA and FQRPa
to each hospital.
Outcomes: The hypotheses to be tested and their outcomes
included: 1) Would hospitals extend an offer for the PI to visit
and give a presentation; 2) in response to the intervention, would
hospitals purposefully change antibiotic use toward greater
diversity; and 3) would resistance rates and proportions of resis-
tant MRSA and FQRPa improve following a change toward
greater diversity of use.
Implementation Strategy: An e-mail was sent in the summer of
2006 to pharmacy and infection control personnel at 17 hospi-
tals with low diversity (above). This text of the message included
a brief review of the potential value of diversity, each hospital’s
diversity score and an offer to provide the intervention (above).
The intervention had to occur by the end of 2006, and 5 hospi-
tals responded positively. The last of 5 interventions was made
on 12/5/06.
Results: It is too early to say if hospitals will adopt policies to
change antibiotic use that will result in greater diversity of use
during 2006, but it appears doubtful for the following reasons:
1) The “diversity hypothesis” does not seem to be familiar to
many of the contact persons; 2) the potential beneﬁt of diversity
of antibiotic use is not yet established; only two small-scale
prospective investigations have been published; 3) antibiotic for-
mularies and antibiotic use appear to be driven more by acqui-
sition costs of therapy than by concerns regarding resistance; and
4) programs to implement greater diversity will probably require
an increase in the use of relatively expensive antibiotics, such as
the carbapenems.
Lessons Learned: 1) In retrospect, it may have been preferable
to select hospitals for intervention based on resistance rates (e.g.,
resistance rates greater that the median value), rather than on
diversity of antibiotic use (i.e., D less than the median value).
This strategy may have generated more offers for the interven-
tion. 2) The costs of bacterial resistance are not well studied and
an argument that a reduction in rates of resistance will carry cost
beneﬁts is difﬁcult to make at this time. 3) The methods that can
be used by a hospital that will result in greater diversity of
antibacterial drug use and that are relatively straight-forward
and practical are not yet worked out. Computer guided antimi-
crobial selection will be the most feasible method to implement
greater diversity, but this is not yet commonly available.
In spite of these limitations we will continue to monitor
antibiotic use and rates of resistance through 2009 in order to
examine relationships between diversity of use and changes in
rates of bacterial resistance. In addition we will monitor and
measure other relevant and potentially confounding variables
such as infection control efforts, hospital policy toward antibi-
otic use (e.g., formulary restriction, etc.) and the impact of com-
munity acquired (CA) infections on rates of nosocomial
resistance, such as CA-MRSA.
PCASE5
APPLIED PHARMACOECONOMICS IN ACADEMIC MEDICINE:
VALIDATION OF CONCEPT
Schoenhaus R, Daniels C
University of California San Diego, San Diego, CA, USA
Organization: University of California, San Diego Medical
Center
Problem or Issue Addressed: Increasing pharmacy budget &
inappropriate medication use. Rapidly rising inpatient pharmacy
budget, lack of evidence-based guidelines for medication use, and
potentially unsafe medication practices created opportunity for
improvement within the University of California, San Diego
Medical Center (UCSDMC) Inpatient Services.
Goals: Goals for the applied pharmacoeconomics pharmacist
specialist position included “hard-dollar” savings to exceed
180% of salary expense after 1 year. Savings were to include
decreased drug expense only, excluding cost-avoidance. Clinical
outcomes research was to be performed to ensure quality of
patient care was improved or maintained.
Outcomes items used in the decision: Clinical and ﬁnancial out-
comes are being assessed through a unique total cost of patient
care model and multiple medication use evaluation projects.
Ongoing outcomes research is based on medical chart review,
trends in DRG coding data, and true changes in patient expense
tracked through TSI Eclipsys® mainframe hospital data linked
to patient encounter(s). Comparisons will also be made to
reported clinical outcomes at other academic medical centers
using the UHC Clinical Resource Manager Database®.
Implementation Strategy: Initial review of current medication use
practice yielded several ideas for projects with high potential
return on investment. Collaboration with various surgical and
medicine stakeholders resulted in improved medication use
policy, stricter criteria for medication use, and research plans 
to assess outcomes. Enforcement of formulary policy was
achieved through changes in practice supported by theUCSDMC
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Pharmacy & Therapeutics (P&T) Committee, including indica-
tion-speciﬁc medication order sets in the computerized provider
order entry (CPOE) system. Compliance with therapeutic sub-
stitutions or changes in preferred medication use was rapid,
mainly due to provider inability to circumvent indication-speciﬁc
drug and dosage recommendations programmed into the order
entry system. Major pharmacoeconomics projects included
improved VTE prophylaxis with emphasis on prioritizing a
single low-molecular weight heparin (LMWH), cost-saving 
antifungal therapeutic substitutions, appropriate use of factor
VIIa in abdominal transplant and aprotinin in cardiothoracic
surgery.
Results: Financial return on investment on the selected
UCSDMC pharmacoeconomic projects exceeded goals for the
new pharmacist position. Projects were all initiated within the
Medical Center between February and April 2006. As of Novem-
ber 2006 approximate cost savings to date were: VTE prophy-
laxis ($29K), antifungal substitutions ($212K), factor VIIa
($140K) and aprotinin ($80K). Projected annual savings for
these projects is anticipated to reach $800,000. Considering
salary and beneﬁts for the new pharmacist specialist position,
annualized beneﬁt to cost ratio will be approximately seven. In
other words, for every dollar spent on an applied pharmacist spe-
cialist roughly $7.00 was returned in actual drug savings. All
medication-related savings were calculated using actual direct
costs to UCSDMC (i.e., no charge or charge to cost ratios were
utilized). Financial savings from improved patient safety (i.e.,
fewer adverse events) through appropriate medication use has
not yet been quantiﬁed, but is anticipated to be substantial.
Lessons Learned: The rapid success of the applied pharma-
coeconomics projects within UCSDMC suggests a similar strat-
egy may be beneﬁcial at other academic medical centers.
Financially responsible medication use does not necessarily result
in inferior patient outcomes when evidence-based guidelines are
enforced through a multidisciplinary process. In fact, such a
process may ultimately result in superior ﬁnancial and clinical
outcomes for patients.
PCASE6
CLINICAL OUTCOMES ASSESSMENT IN BEHAVIORAL
HEALTH CARE: SEARCHING FOR PRACTICAL SOLUTIONS
Madan A, Borckardt J,Weinstein B,Wagner M, Cooney H, Herbert J
Medical University of South Carolina, Charleston, SC, USA
Organization: Medical University of South Carolina, Depart-
ment of Psychiatry and Behavioral Science, Charleston, SC
29425, USA.
Problem or Issue Addressed: Many national quality management
initiatives in behavioral health care have focused on tracking and
managing adverse events, clinical processes measures, and cost
variables. Relatively less attention has been paid to indices of
clinical improvement.
Goals: In response to an administrative need for systematic out-
comes assessments within an expanding quality management
program, the authors developed a web-based patient-reported
outcomes management system (Psychiatry Clinical Outcomes
Management System [PSYCOMS]) to assess patients’ endorse-
ment of psychiatric symptomatology at each outpatient clinic
visit. Rather than create an infrastructure limited to providing
only evaluation of overall clinic performance, the authors devel-
oped a system capable of providing additional evaluation of clin-
ical functioning at the patient/clinician level. While providing the
necessary outcomes data related to clinical efﬁcacy, the authors
aimed to develop the PSYCOMS system to be: brief, simple,
valuable, relevant, acceptable, and available, thus in line with
recommendations in the scientiﬁc literature regarding outcomes
assessment protocols.
Outcomes items used in the decision: One of the major goals in
the development of the PSYCOMS system was to keep the focus
on practicality and utility rather than conventionality. As such,
the authors developed a brief but comprehensive (12-item), orig-
inal symptom checklist that was designed to capture a full array
of psychiatric problems. The rating-system was designed to
mimic numeric rating scales (simple) that are often used in clin-
ical practice to quantify level of distress or dysfunction (partic-
ularly in pain management where clinicians routinely ask
patients to rate their level of pain using a 1 to 10 scale). The
authors modiﬁed this approach to capture a full array of psy-
chiatric issues (valuable and relevant) rather than focus on
disease-speciﬁc symptom clusters. Preliminary psychometric
analyses indicate adequate internal consistency (alpha = 0.85)
and good item-total correlations; however, the scale was not
designed to comprehensively capture a comprehensive picture of
psychiatric disorders and functioning. Rather, the goal was to get
a quick “snapshot” of patients’ symptom distress and/or dys-
function across a full array of clinical problems.
Implementation Strategy: Using simple HTML and PHP scripts
the authors developed an online administration of the symptom
checklist, allowing for automatic entry of data into a centralized
database and real-time clinical progress reports at the
patient/clinician level. Additionally, higher-level clinic perfor-
mance dashboards have been made available online for admin-
istrative review of patient functioning and/or clinic performance
over time. The website is housed on the local intranet, protected
behind a ﬁrewall, and cannot be accessed from outside the
network. Limited patient information is stored in the database
(e.g., only encrypted medical record numbers, age and sex) to
minimize internet security risks and eliminate the possibility of
unauthorized access to patient information.
Results: Preliminary data suggest that administrative staff and
patients tolerate the data collection tool well. There have been
minimal problems with patients not knowing how to point and
click (or touch the screen) on their numeric ratings. By staff
report, the rating scale takes, on average, less than one minute
to complete. Clinicians ﬁnd the patient-level reports useful in
tracking patient symptoms over time, and hospital administra-
tors appreciate the availability of timely reports capable of pro-
viding meaningful information at the patient, clinician, and clinic
level. Informal training on accessing the data took approximately
30 minutes.
Lessons Learned: Despite the initial cost of purchasing hardware
(∼$500/clinic), the PSYCOMS system is largely self-contained
and requires little maintenance. Accessing the database and con-
verting data to a speciﬁed ﬁle format (e.g., Microsoft Excel) is
relatively easy, but more complex analyses and drill-downs
require trained quality and outcomes management and adminis-
trative personnel. Of note, the authors have had to limit clini-
cians and administrators from making causal inferences based
on data collected through this system. While not capable of pro-
viding causal information, tracking clinical improvement can
yield important and useful patient and clinic level information,
especially if clinic-level performance seems to indicate that
patients are not improving as a function of visits to the clinic,
potentially prompting a closer look at the needs of the patients
and the services provided within a clinic.
